Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis
36:06
A Challenging Odyssey through AML: Confronting aGvHD, TMA, PRES after alloHCT
32:59
Management of Waldenstrom disease: an update
49:06
Post #ASH24 Most Important CLL Studies
53:00
Multiple Myeloma: Highlights from #ASH24
43:48
Post #ASH24 Most Important Cellular Therapy Studies
42:29
Impact of prior treatment on selinexor bortezomib dexamethasone outcomes in patients with relapse mm
56:25
Post #ASH24 Most Important MDS Studies
58:20